- Home
- EVER vs XNCR Comparison
EVER vs XNCR Comparison
Compare EVER & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVER | XNCR |
|---|---|---|
| Founded | 2008 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.5M | 881.9M |
| IPO Year | 2018 | 2013 |
Fundamental Metrics
Financial Performance| Metric | EVER | XNCR |
|---|---|---|
| Price | $16.49 | $12.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $27.00 | $22.89 |
| AVG Volume (30 Days) | ★ 1.1M | 644.9K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 198.86 | 65.36 |
| EPS | ★ 2.63 | N/A |
| Revenue | ★ $163,349,000.00 | $125,576,000.00 |
| Revenue This Year | $14.68 | N/A |
| Revenue Next Year | $11.86 | $6.52 |
| P/E Ratio | $6.17 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $13.93 | $6.92 |
| 52 Week High | $30.03 | $18.69 |
Technical Indicators
Market Signals| Indicator | EVER | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 48.51 |
| Support Level | $13.93 | $10.92 |
| Resistance Level | $17.59 | $12.73 |
| Average True Range (ATR) | 0.83 | 0.90 |
| MACD | 0.35 | 0.04 |
| Stochastic Oscillator | 64.55 | 34.18 |
Price Performance
Historical ComparisonAbout EVER EverQuote Inc.
EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.